308 related articles for article (PubMed ID: 28478717)
1. Selexipag, an Oral Prostacyclin-Receptor Agonist for Pulmonary Arterial Hypertension.
Baker WL; Darsaklis K; Singhvi A; Salerno EL
Ann Pharmacother; 2017 Jun; 51(6):488-495. PubMed ID: 28478717
[TBL] [Abstract][Full Text] [Related]
2. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D
Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448
[TBL] [Abstract][Full Text] [Related]
3. Selexipag for the treatment of pulmonary arterial hypertension.
Noel ZR; Kido K; Macaulay TE
Am J Health Syst Pharm; 2017 Aug; 74(15):1135-1141. PubMed ID: 28533253
[TBL] [Abstract][Full Text] [Related]
4. Selexipag for the Treatment of Pulmonary Arterial Hypertension.
Sitbon O; Channick R; Chin KM; Frey A; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; Preiss R; Rubin LJ; Di Scala L; Tapson V; Adzerikho I; Liu J; Moiseeva O; Zeng X; Simonneau G; McLaughlin VV;
N Engl J Med; 2015 Dec; 373(26):2522-33. PubMed ID: 26699168
[TBL] [Abstract][Full Text] [Related]
5. Selexipag: A Review in Pulmonary Arterial Hypertension.
Duggan ST; Keam SJ; Burness CB
Am J Cardiovasc Drugs; 2017 Feb; 17(1):73-80. PubMed ID: 27988834
[TBL] [Abstract][Full Text] [Related]
6. Selexipag for the treatment of pulmonary arterial hypertension.
Richter MJ; Gall H; Grimminger J; Grimminger F; Ghofrani HA
Expert Opin Pharmacother; 2016 Sep; 17(13):1825-34. PubMed ID: 27467883
[TBL] [Abstract][Full Text] [Related]
7. Selexipag for the treatment of pulmonary arterial hypertension.
Skoro-Sajer N; Lang IM
Expert Opin Pharmacother; 2014 Feb; 15(3):429-36. PubMed ID: 24392948
[TBL] [Abstract][Full Text] [Related]
8. Selexipag: First Global Approval.
Scott LJ
Drugs; 2016 Mar; 76(3):413-8. PubMed ID: 26846322
[TBL] [Abstract][Full Text] [Related]
9. Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension.
Bruderer S; Hurst N; Remenova T; Dingemanse J
Expert Opin Drug Saf; 2017 Jun; 16(6):743-751. PubMed ID: 28494686
[TBL] [Abstract][Full Text] [Related]
10. Selexipag in Pulmonary Arterial Hypertension: Most Updated Evidence From Recent Preclinical and Clinical Studies.
Ghosh RK; Ball S; Das A; Bandyopadhyay D; Mondal S; Saha D; Gupta A
J Clin Pharmacol; 2017 May; 57(5):547-557. PubMed ID: 27670133
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic drug evaluation of selexipag for the treatment of pulmonary arterial hypertension.
Sardana M; Moll M; Farber HW
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1513-1520. PubMed ID: 27756196
[TBL] [Abstract][Full Text] [Related]
12. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI
Preston IR; Channick RN; Chin K; Di Scala L; Farber HW; Gaine S; Galiè N; Ghofrani HA; Hoeper MM; Lang IM; McLaughlin VV; Preiss R; Simonneau G; Sitbon O; Tapson VF; Rubin LJ
J Heart Lung Transplant; 2018 Mar; 37(3):401-408. PubMed ID: 29096938
[TBL] [Abstract][Full Text] [Related]
13. Determining the value contribution of selexipag for the treatment of pulmonary arterial hypertension (PAH) in Spain using reflective multi-criteria decision analysis (MCDA).
Jiménez A; Ais A; Beaudet A; Gil A
Orphanet J Rare Dis; 2018 Dec; 13(1):220. PubMed ID: 30526673
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and Safety of an Orally Administered Selective Prostacyclin Receptor Agonist, Selexipag, in Japanese Patients With Pulmonary Arterial Hypertension.
Tanabe N; Ikeda S; Tahara N; Fukuda K; Hatano M; Ito H; Nakayama T; Anzai T; Hashimoto A; Inoue T; Kajinami K; Kihara Y; Kinoshita H; Kuwahara K; Murohara T; Okazaki O; Sakai S; Satoh T; Takeda Y; Takeishi Y; Taniguchi M; Watanabe H; Yamamoto T; Yamauchi-Takihara K; Yoshioka K; Sasayama S
Circ J; 2017 Aug; 81(9):1360-1367. PubMed ID: 28420826
[TBL] [Abstract][Full Text] [Related]
15. Selexipag for the treatment of pulmonary arterial hypertension.
Sharma K
Expert Rev Respir Med; 2016; 10(1):1-3. PubMed ID: 26567613
[TBL] [Abstract][Full Text] [Related]
16. Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
Galiè N; Gaine S; Channick R; Coghlan JG; Hoeper MM; Lang IM; McLaughlin VV; Lassen C; Rubin LJ; Hsu Schmitz SF; Sitbon O; Tapson VF; Chin KM
Adv Ther; 2022 Jan; 39(1):796-810. PubMed ID: 34727317
[TBL] [Abstract][Full Text] [Related]
17. Selexipag: an oral, selective prostacyclin receptor agonist for the treatment of pulmonary arterial hypertension.
Simonneau G; Torbicki A; Hoeper MM; Delcroix M; Karlócai K; Galiè N; Degano B; Bonderman D; Kurzyna M; Efficace M; Giorgino R; Lang IM
Eur Respir J; 2012 Oct; 40(4):874-80. PubMed ID: 22362844
[TBL] [Abstract][Full Text] [Related]
18. An evaluation of selexipag for the treatment of pulmonary hypertension.
Panagiotidou E; Boutou A; Pitsiou G
Expert Opin Pharmacother; 2021 Jan; 22(1):29-36. PubMed ID: 32867545
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacological characteristics and clinical study results of Selexipag (Uptravi
Kuwano K; Kosugi K; Fuchikami C; Funaki S
Nihon Yakurigaku Zasshi; 2021; 156(3):178-186. PubMed ID: 33952848
[TBL] [Abstract][Full Text] [Related]
20. Real-Life Experience with Selexipag as an Add-On Therapy to Oral Combination Therapy in Patients with Pulmonary Arterial or Distal Chronic Thromboembolic Pulmonary Hypertension: A Retrospective Analysis.
Berlier C; Schwarz EI; Saxer S; Lichtblau M; Ulrich S
Lung; 2019 Jun; 197(3):353-360. PubMed ID: 30963265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
